Microbial Drug Resistance

metrics 2024

Pioneering Insights in Microbial Resistance and Pharmacology

Introduction

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.

Metrics 2024

SCIMAGO Journal Rank0.60
Journal Impact Factor2.30
Journal Impact Factor (5 years)3.50
H-Index78
Journal IF Without Self2.30
Eigen Factor0.00
Normal Eigen Factor0.88
Influence0.73
Immediacy Index0.40
Cited Half Life5.50
Citing Half Life7.60
JCI0.57
Total Documents2226
WOS Total Citations4092
SCIMAGO Total Citations17477
SCIMAGO SELF Citations862
Scopus Journal Rank0.60
Cites / Document (2 Years)2.40
Cites / Document (3 Years)2.43
Cites / Document (4 Years)2.54

Metrics History

Rank 2024

Scopus

Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #119/313
Percentile 61.98
Quartile Q2
Microbiology (medical) in Medicine
Rank #56/140
Percentile 60.00
Quartile Q2
Microbiology in Immunology and Microbiology
Rank #79/182
Percentile 56.59
Quartile Q2
Immunology in Immunology and Microbiology
Rank #121/236
Percentile 48.73
Quartile Q3

IF (Web Of Science)

INFECTIOUS DISEASES
Rank 81/132
Percentile 39.00
Quartile Q3
MICROBIOLOGY
Rank 109/161
Percentile 32.60
Quartile Q3
PHARMACOLOGY & PHARMACY
Rank 199/354
Percentile 43.90
Quartile Q3

JCI (Web Of Science)

INFECTIOUS DISEASES
Rank 69/132
Percentile 47.73
Quartile Q3
MICROBIOLOGY
Rank 90/161
Percentile 44.10
Quartile Q3
PHARMACOLOGY & PHARMACY
Rank 210/354
Percentile 40.68
Quartile Q3

Quartile History

Similar Journals

Indian Journal of Medical Microbiology

Your Gateway to Open Access Microbiological Research
Publisher: ELSEVIERISSN: 0255-0857Frequency: 4 issues/year

Indian Journal of Medical Microbiology, published by Elsevier, is a pivotal peer-reviewed journal dedicated to the field of medical microbiology, providing a vital platform for research and scholarship since its inception in 1986. With an Open Access model established in 2001, it ensures the dissemination of scientific knowledge to a global audience, enhancing accessibility for researchers, professionals, and students alike. The journal's scope spans critical areas including immunology, infectious diseases, and microbiology, with an impressive trajectory marked by converged years of publication allowing for a comprehensive exploration of evolving scientific trends. As of 2023, the journal holds a Q3 ranking in Infectious Diseases and Microbiology (medical) and a Q4 ranking in Immunology and Microbiology categories, reflecting its significant yet growing impact in the field. Researchers seeking to contribute to or stay updated on the latest advancements in medical microbiology will find the Indian Journal of Medical Microbiology a valuable resource, as it consistently bridges the gap between emerging science and clinical application.

GERMS

Advancing global health through innovative research.
Publisher: EUROPEAN ACAD HIV-AIDS & INFECTIOUS DISEASESISSN: 2248-2997Frequency: 4 issues/year

GERMS is a multidisciplinary journal published by the EUROPEAN ACAD HIV-AIDS & INFECTIOUS DISEASES, dedicated to advancing knowledge in the fields of epidemiology, immunology, infectious diseases, and microbiology. Since its inception in 2011, the journal has provided a crucial platform for researchers and practitioners to share innovative studies, clinical findings, and public health insights, with an eye on improving health outcomes globally. With an ISSN of 2248-2997 and a consistent publication trajectory leading up to 2024, GERMS is recognized in the third quartile across several categories, reflecting its growing impact and relevance in the scientific community. Authors and readers benefit from a range of access options, fostering the dissemination of vital research findings. As a journal situated in Romania, it also addresses regional health challenges while contributing to the broader discourse on infectious diseases and public health. GERMS is not just a repository of knowledge, but a vital resource for those engaged in combating infectious diseases and promoting health equity.

Infection and Drug Resistance

Illuminating the path to effective therapeutic interventions.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1178-6973Frequency: 1 issue/year

Infection and Drug Resistance, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the critical fields of infectious diseases and pharmacology. Since its establishment in 2008, this journal has emerged as a vital resource for researchers, professionals, and students alike, offering thorough insights into the mechanisms of drug resistance and the effectiveness of various therapeutic interventions. With an impressive 2023 impact factor placing it in the Q2 category across multiple relevant disciplines, including Infectious Diseases and Pharmacology, it serves as a significant platform for high-quality research dissemination. Infection and Drug Resistance aims to foster a deeper understanding of the evolving challenges in managing infectious diseases and enhancing drug efficacy, contributing to the global discourse on public health. The journal's commitment to open access ensures that vital knowledge is readily available to promote broader scholarly engagement and innovation.

Revista Espanola de Quimioterapia

Transforming Research into Real-World Impact
Publisher: SOCIEDAD ESPANOLA QUIMIOTERAPIAISSN: 0214-3429Frequency: 6 issues/year

The Revista Espanola de Quimioterapia, published by the SOCIEDAD ESPANOLA QUIMIOTERAPIA, is a pivotal open-access journal that has been advancing the field of clinical microbiology and pharmacology since its inception in 1989. With an E-ISSN of 1988-9518, this journal caters to a diverse audience of researchers, healthcare professionals, and students, providing them with critical insights into the latest developments in medicinal chemistry and therapeutic strategies. Located in Madrid, Spain, the journal reflects the rigorous academic standards of its associated institutions, contributing significantly to the translation of research into clinical practice. Achieving a Q3 ranking in the fields of Medicine, Microbiology, and Pharmacology in 2023 attests to its growing influence and relevance in the scientific community, making it a vital resource for those engaged in the quest for innovative solutions to pressing healthcare challenges. The journal prides itself on its commitment to maintaining an open-access model since 2018, ensuring that vital research is freely accessible to foster greater knowledge sharing and collaboration within the global scientific community.

Malaysian Journal of Microbiology

Connecting Research and Practice in Applied Microbiology
Publisher: MALAYSIAN SOC MICROBIOLOGYISSN: 1823-8262Frequency: 6 issues/year

Malaysian Journal of Microbiology is a prestigious open-access journal dedicated to advancing the field of microbiology, published by the Malaysian Society for Microbiology. Since its inception in 2005, this journal has become an essential platform for researchers and practitioners, facilitating the dissemination of innovative studies in applied microbiology, biotechnology, and infectious diseases. Based in Penang, Malaysia, this journal not only focuses on local microbiological research but also positions itself within the broader global scientific community. Although currently placed in the Q4 category in several relevant fields—including Applied Microbiology and Biotechnology, Infectious Diseases, and Medical Microbiology according to the 2023 Scopus rankings—it plays a crucial role in encouraging novel research and fostering collaboration among scientists. The journal encourages submissions that contribute to the understanding of microbial processes, disease mechanisms, and novel biotechnological applications, thereby supporting the continuous growth of knowledge in microbiology. With open access since its launch, the Malaysian Journal of Microbiology ensures that all published works are freely available to the public, enhancing their visibility and impact within the scientific community.

BMC MICROBIOLOGY

Transforming health and environment through microbiological excellence.
Publisher: BMCISSN: 1471-2180Frequency: 1 issue/year

BMC Microbiology is a leading open access journal published by BMC, dedicated to advancing the field of microbiology since its inception in 2001. With an ISSN of 1471-2180, this journal provides a vital platform for researchers, professionals, and students to share and access high-quality research and innovation in both general and medical microbiology. Based in the United Kingdom, BMC Microbiology holds a commendable Q2 ranking in both various microbiological categories according to the 2023 Scopus rankings, indicating its strong influence in the microbiological community, with a rank of #47 out of 140 in Medical Microbiology and #62 out of 182 in general Microbiology. The journal's commitment to open access ensures that groundbreaking research is freely available to facilitate collaboration and knowledge sharing among the global community of microbiologists. With a focus on publishing original research, reviews, and case studies, BMC Microbiology plays a critical role in disseminating information that can impact health and environmental conditions around the world.

Journal of Global Antimicrobial Resistance

Empowering research to combat resistance worldwide.
Publisher: ELSEVIER SCI LTDISSN: 2213-7165Frequency: 4 issues/year

The Journal of Global Antimicrobial Resistance, published by Elsevier Scientific Ltd, is a premier open access journal dedicated to addressing the critical issue of antimicrobial resistance on a global scale. Established in 2013 and significantly gaining traction as an open access platform since 2020, this journal serves as an essential resource for researchers, healthcare professionals, and policy makers invested in immunology, microbiology, and associated fields. With an impressive impact factor reflected through its consistent ranking in the Q2 category across multiple disciplines, including Microbiology and Immunology – where it ranks #29 out of 140 in Medical Microbiology – the journal ensures high-quality peer-reviewed articles that push the boundaries of current knowledge and practice. By offering a global perspective on research trends and public health implications, the Journal of Global Antimicrobial Resistance plays a pivotal role in advancing the scientific discourse necessary to combat the rising tide of antimicrobial resistance worldwide.

Expert Review of Anti-Infective Therapy

Navigating the Frontiers of Infectious Disease Solutions
Publisher: TAYLOR & FRANCIS LTDISSN: 1478-7210Frequency: 12 issues/year

Expert Review of Anti-Infective Therapy, published by Taylor & Francis Ltd, is a leading journal in the field of infectious diseases, microbiology, and virology, boasting an impressive impact factor and ranking in the Q1 category across multiple disciplines. With an ISSN of 1478-7210 and E-ISSN 1744-8336, this journal has become a vital resource for researchers, professionals, and students aiming to advance their understanding of anti-infective therapies. Since its inception in 2003, the journal has provided critical insights, evidence-based reviews, and forward-thinking perspectives that contribute significantly to the ongoing efforts in combating infectious diseases. As of 2023, it ranks #36 out of 344 in Medicine/Infectious Diseases and maintains high percentiles in various other categories, reflecting its influence and reach within the scientific community. Although not an Open Access journal, its rich content is delivered through various academic libraries, sustaining its commitment to disseminating knowledge in the face of global health challenges. For those committed to innovation in the field, the Expert Review of Anti-Infective Therapy offers a platform that blends thorough research with practical applications, making significant strides in the fight against infectious pathogens.

Antibiotics-Basel

Empowering the fight against infectious diseases through innovative research.
Publisher: MDPIISSN: 2079-6382Frequency: 12 issues/year

Antibiotics-Basel is a prestigious multidisciplinary journal published by MDPI, dedicated to advancing the field of antibiotic research and management. Since its inception in 2012 as an Open Access publication, the journal has established itself as a vital resource for researchers and professionals, offering an accessible platform for the dissemination of innovative findings in Biochemistry, Infectious Diseases, Microbiology, and Pharmacology. With a solid impact in its category, Antibiotics-Basel holds a Q1 ranking in critical areas such as Pharmacology and Pharmacology, Toxicology and Pharmaceutics, making it an influential journal in its field. The journal publishes high-quality research articles, reviews, and communications that are essential for advancing our understanding of antibiotic mechanisms, resistance, and therapeutic applications. Researchers are invited to submit their manuscript to contribute to this growing body of knowledge and collaborate in the fight against antibiotic resistance and infectious diseases.

JOURNAL OF CHEMOTHERAPY

Elevating Standards in Chemotherapy Research
Publisher: TAYLOR & FRANCIS LTDISSN: 1120-009XFrequency: 6 issues/year

Journal of Chemotherapy is a distinguished peer-reviewed academic journal published by Taylor & Francis Ltd, focusing on the dynamic fields of infectious diseases, oncology, and pharmacology. With its ISSN 1120-009X and E-ISSN 1973-9478, this journal has been at the forefront of chemotherapy research since its inception in 1989 and continues to play a vital role in advancing medical science through rigorous studies and reviews. It currently holds a respectable position in various Scopus categories, ranked Q3 in several important disciplines, reflecting its commitment to providing quality research. Although it operates under a subscription model, Journal of Chemotherapy remains a crucial resource for practitioners and academics alike, facilitating knowledge exchange and innovation in the treatment of diseases through chemotherapy. With access to the latest findings and therapeutic advancements, this journal is a must-read for researchers, medical professionals, and students seeking to enhance their understanding of emerging trends in chemotherapy.